| Expression pattern: |
UP |
| Associated gene: |
SLC25A15 |
| Associated microRNA: |
miR-29a-3p |
| Biological function: |
promotes prostate cancer cell proliferation and cell cycle progression; inhibits apoptosis |
| Molecular mechanism: |
ceRNA mechanism: circFOXO3 sponges miR-29a-3p to up-regulate SLC25A15 |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Luciferase Reporter Assay; RNA Pull-Down; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circFOXO3 expression in PCa serum samples was significantly higher than those in normal samples, suggesting circFOXO3 could acted as a diagnostic biomarker of PCa; circFOXO3 was positively correlated with the Gleason score in PCa samples |
| Description: |
circFOXO3 is up-regulated in prostate cancer tissues and serum and promotes PCa cell proliferation and cell-cycle progression while inhibiting apoptosis. Mechanistically, it acts as a ceRNA sponge for miR-29a-3p, thereby relieving repression of SLC25A15 and contributing to PCa progression; it may also have diagnostic biomarker potential in serum. |
| Confidence score: |
0.8246 |